Rheumatoid arthritis has no cure – but researchers are homing in on preventing it

Rheumatoid arthritis, an autoimmune and inflammatory condition, affects more than 18 million people globally, including nearly 1.5 million Americans. This disease causes the body’s immune system to attack its own joints, leading to pain, stiffness, and swelling. Even with treatment, rheumatoid arthritis can cause significant disability, impacting daily activities like preparing food or getting dressed.

A Shift Towards Prevention

Traditionally, rheumatoid arthritis has been treated after symptoms appear. However, a growing body of evidence suggests the possibility of identifying the disease earlier, and potentially even preventing it. A physician and researcher specializing in rheumatoid arthritis, who has conducted clinical trials on treatments for the condition, believes this research could fundamentally change how the disease is managed in the coming years.

Did You Know? Up to 80% of people with rheumatoid arthritis have detectable autoantibodies – rheumatoid factor and anti-cyclic citrullinated peptide – in their blood.

Currently, diagnosis involves examining joints for swelling and testing for blood markers called autoantibodies. However, research has confirmed the existence of a preclinical stage, occurring three to five years – or longer – before noticeable joint swelling. During this stage, these autoantibodies are present, indicating autoimmune activity, even though the individual may not yet experience symptoms.

Identifying Risk Before Symptoms Appear

Identifying individuals at risk during this preclinical stage involves looking for autoantibodies and symptoms like prolonged early morning joint stiffness. While predicting future rheumatoid arthritis is still in the research phase, the field is working towards routine testing, similar to how cardiovascular risk is assessed through cholesterol measurements.

Expert Insight: The identification of a preclinical stage represents a significant shift in our understanding of rheumatoid arthritis, opening the door to potential preventative interventions rather than solely focusing on managing established disease.

The Promise of Early Intervention

Researchers are now investigating treatments to delay or prevent the full development of rheumatoid arthritis. Trials have been conducted on individuals who tested positive for anti-cyclic citrullinated peptide or have other risk factors, including joint pain and subclinical joint inflammation detected through imaging. These trials primarily utilize existing immune drugs like methotrexate, hydroxychloroquine, and rituximab, testing whether a short course can “reset” the immune system.

While no drug is currently approved for rheumatoid arthritis prevention, these studies offer hope. Further research is focused on understanding the biology of the preclinical stage, which was previously overlooked in favor of studying those with full-blown arthritis. Studies are revealing immune system abnormalities in cells, autoantibodies, and inflammation during this stage.

Exploring the Mucosal Origins Hypothesis

Emerging research suggests the early autoimmunity of rheumatoid arthritis may originate in inflammation at mucosal surfaces – such as the gums, lungs, and gut – with joint involvement occurring later. This “mucosal origins hypothesis” may explain the link between rheumatoid arthritis and conditions like periodontal disease, emphysema, exposure to tobacco smoke, and even certain bacterial associations. Future trials may target these mucosal processes.

However, challenges remain. Approximately 20% to 30% of people positive for anti-cyclic citrullinated peptide antibodies do not develop rheumatoid arthritis, making it difficult to identify suitable participants for prevention trials. Researchers are currently focusing on individuals with early joint symptoms but no swelling, but a broader approach requiring larger, international networks for testing risk factors is likely needed.

Frequently Asked Questions

What is rheumatoid arthritis?

Rheumatoid arthritis is an autoimmune, inflammatory form of arthritis where the immune system attacks the joints, causing pain, stiffness, and swelling.

What is the preclinical stage of rheumatoid arthritis?

The preclinical stage is a period of three to five years or longer before the onset of swollen joints, where markers like rheumatoid factor and anti-cyclic citrullinated peptide are detectable in the blood, indicating autoimmune activity without noticeable symptoms.

Are there treatments to prevent rheumatoid arthritis?

While there is not yet an approved drug for rheumatoid arthritis prevention, trials are being conducted using existing immune drugs to see if they can delay or prevent the disease from developing.

Could a future of preventative care for rheumatoid arthritis become a reality, offering hope for those at risk of developing this debilitating condition?